Ultragenyx Pharmaceutical Inc.
RARE Nasdaq
SEC CIK 1515673
Follow Ultragenyx Pharmaceutical
Weekly email: filings, results
Revenue, last quarter
$173M
+8.1% vs same quarter last year
Net income
−$118M
+34.4% vs same quarter last year
EPS, diluted
−$1.16
+35.9% vs same quarter last year
Operating cash flow
−$43M
+52.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $673M | −$575M |
| FY24 | $560M | −$569M |
| FY23 | $434M | −$607M |
| FY22 | $363.3M | −$707.4M |
| FY21 | $351.4M | −$454M |
| FY20 | $271M | −$186.6M |
| FY19 | $103.7M | −$402.7M |
| FY18 | $51.5M | −$197.6M |
| FY17 | $2.6M | −$302.1M |
| FY16 | $133K | −$245.9M |
| FY15 | - | −$145.6M |
| FY14 | - | −$59.8M |
| FY13 | - | −$35.1M |
| FY12 | - | −$16.3M |
| FY11 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −79.5% | −85.4% |
| FY24 | −95.7% | −101.6% |
| FY23 | −131.1% | −139.9% |
| FY22 | −178.6% | −194.7% |
| FY21 | −108.6% | −129.2% |
| FY20 | −121.8% | −68.8% |
| FY19 | −409% | −388.3% |
| FY18 | −721.2% | −383.7% |
| FY17 | −12593.5% | −11567.3% |
| FY16 | −186471.4% | −184867.7% |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$472M |
| FY24 | −$421M |
| FY23 | −$519M |
| FY22 | −$496.6M |
| FY21 | −$411.8M |
| FY20 | −$176.1M |
| FY19 | −$370.2M |
| FY18 | −$294.6M |
| FY17 | −$256.6M |
| FY16 | −$171.2M |
| FY15 | −$110.9M |
| FY14 | −$46.8M |
| FY13 | −$31.6M |
| FY12 | −$13.6M |
| FY11 | - |
- Ultragenyx Pharmaceutical
- Healthcare median
Show the numbers
| Year | Ultragenyx Pharmaceutical | Healthcare median |
|---|---|---|
| FY25 | −85.4% | −30.6% |
| FY24 | −101.6% | −47% |
| FY23 | −139.9% | −58% |
| FY22 | −194.7% | −80.4% |
| FY21 | −129.2% | −71.8% |
| FY20 | −68.8% | −62.2% |
| FY19 | −388.3% | −46.2% |
| FY18 | −383.7% | −49.6% |
| FY17 | −11567.3% | −45.9% |
| FY16 | −184867.7% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |